Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03201757 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 523
- Enrollment target
NCT03201757: Completed Phase 3 study, sponsored by Alkermes.
NCT03201757 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 523 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03201757, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 523 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
Interventions
- DRUG ALKS 3831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 3 |
What the finished NCT03201757 record still lists
NCT03201757 is an interventional study that assigns participants to a tested intervention. The registered 523 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which ALKS 3831 is the first listed.
NCT03201757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03201757 about?
NCT03201757 is a clinical study titled "Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831". This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
What is the current status of trial NCT03201757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 523 participants. The study started on 2017-06-15. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT03201757?
The interventions under investigation include: ALKS 3831 (DRUG).
Who is sponsoring clinical trial NCT03201757?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03201757's enrollment target sits among peer trials
523 716th of 2000 higher than 1,285 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI